EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) exon 19 insertions are rare mutations in non-small cell lung cancer (NSCLC).
• The clinical response of these rare mutations to tyrosine kinase inhibitors (TKIs) remains uncertain.
• This study investigates the efficacy of TKIs in patients with EGFR exon 19 insertions.

Purpose of the Study:

• To evaluate the treatment outcomes of NSCLC patients with EGFR exon 19 insertions.
• To review existing literature on the response of EGFR exon 19 insertions to various TKIs.
• To determine if these patients benefit from EGFR-targeted therapies.

Main Methods:

• Screening of 1,046 NSCLC tumor samples for EGFR mutations using direct or next-generation sequencing.
• Detailed analysis of two patients with identical 18-nucleotide EGFR exon 19 insertions treated with afatinib.
• Comprehensive literature review of clinical data for patients with EGFR exon 19 insertions treated with TKIs.

Main Results:

• Both reported patients achieved stable disease with afatinib, experiencing progression-free survival (PFS) of 6 and 10 months, and overall survival (OS) of 17 and 19 months.
• Pooled analysis (n=28) of literature data and the current cases revealed a 64% response rate and 92% disease control rate to TKIs.
• Median PFS was 9 months, and median OS was 13 months across all TKIs, comparable to outcomes seen with classical EGFR mutations.

Conclusions:

• EGFR exon 19 insertions confer sensitivity to EGFR TKIs in NSCLC.
• Patients diagnosed with EGFR exon 19 insertions should be considered for treatment with EGFR TKIs.
• These findings support the use of targeted therapy for rare EGFR mutations in NSCLC.